- ISIN: US0191141078
- Land: .
Nachricht vom 18.09.2019 | 17:10
Allied Corp. Signs Letter of Intent with Evoke Neurosciences to Partner on the Analysis and Treatment of PTSD Patients
DGAP-News: Allied Corp.
/ Key word(s): Miscellaneous
Kelowna, British Columbia--(Newsfile Corp. - September 18, 2019) - Allied Corp. (OTC Pink: ALID) ("Allied"), an international medical cannabis production company focused on creating and providing targeted cannabinoid health solutions, is pleased to announce its signing of a Letter Of Intent ("the LOI") with Evoke Neurosciences ("Evoke"). Evoke's eVox System generates an objective and automated report for clinicians and researchers to use as a baseline and to aid diagnosis and facilitate treatment planning for patients living with PTSD. Under the LOI, Allied would employ Evoke's eVox System to assess the function of the Central and Autonomic Nervous System via EEG, ECG, and Event-Related Potentials (ERPs).
This data is collected via an easy-to-use, FDA-cleared, class 2 medical device that acquires patient data non-invasively in a clinical setting. With the eVox System, clinicians can establish a baseline of the patient's brain function, monitor treatment effects and measure changes in brain function. Additionally, clinicians who use the eVox System have found that the objective data facilitates a greater buy-in from patients that can lead to increased patient adherence.
This mutually beneficial partnership between Allied and Evoke would be characterized by the following:
"We are extremely excited to partner with Evoke," said Calum Hughes, CEO of Allied Corp. "This partnership not only facilitates a greater understanding of PTSD, but it also accelerates the path to treatment for veterans and first responders. We believe that by utilizing the eVox technology, we would accumulate essential data that will aid in further developing a better therapeutic solution."
About Evoke Neuroscience
Evoke Neuroscience was formed in 2009 with the mission to improve diagnosis and treatment of cognitive disorders with objective, clinically meaningful and easy-to-use products. Physicians use the eVox® System to acquire objective and stable biomarkers that may aid in the diagnosis of cognitive diseases such as dementia. Evoke was named one of the INC. 500/5000 fastest growing companies two years in a row.
About Allied Corp.
Allied Corp. is an international medical cannabis production company with a mission to address today's medical issues by researching, creating and producing targeted cannabinoid health solutions. Allied Corp. uses an evidence-informed scientific approach to make this mission possible, through cutting-edge pharmaceutical research and development, innovative plant-based production and unique development of therapeutic products.
This news release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements relate to future events or future performance. Statements which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, outlook, expectations or intentions regarding the future including words or phrases such as "anticipate", "become", "objective", "may", "will", "might", "should", "could", "can", "intend", "expect", "believe", "estimate", "predict", "potential", "plan", "is designed to", "project", "continue", or similar expressions suggest future outcomes or the negative thereof or similar variations. Such forward-looking statements include, but are not limited to, that the company will be able to launch its proposed hemp-derived retail product line, TACTICAL RELIEF™, that such product will relieve symptoms caused by trauma, and that such products will be accepted by service members and first responders. We are subject to various additional risks as described in our SEC filings at www.SEC.gov.
Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price.
We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/47891
Click on, or paste the following link into your web browser,to view the associated documents http://www.newsfilecorp.com/release/47891
News Source: Newsfile
|EQS News ID:||876067|
|End of News||DGAP News Service|
Expedeon AG mit attraktiver Produktpipeline
Durch die konsequente Fortsetzung der „Grow, Buy & Build“-Strategie hat die im Bereich der Entwicklung und Vermarktung von DNA-Technologien, Proteomik- und Antikörper-Konjugations-Anwendungen tätige Expedeon AG das Umsatzniveau angehoben und auf operativer Ergebnisebene zugleich den Break-Even nachhaltig überschritten. Für die kommenden Perioden ist der Ausbau der Umsatzerlöse mit den bestehenden Produkten geplant. Darüber hinaus verfügt die Expedeon AG über eine attraktive Produktpipeline mit hohem Umsatzpotenzial. Unser Kursziel liegt bei 3,20 € je Aktie. Das Rating lautet KAUFEN.
Der AKTIONÄR News
19. Oktober 13:59 Amazon, Netflix und Co: So geht es weiter
19. Oktober 12:15 Gilead-Partner Sangamo: "Bisher sehen die Daten vielversprechend aus"
19. Oktober 08:00 Übernahmeschlacht um ThyssenKrupp – was plant Kone?
19. Oktober 07:10 Wirecard: Jetzt ist Schluss!
19. Oktober 07:00 Die Wochen der Wahrheit - potenzielle Gewinner und Verlierer der ...
News im Fokus
Wirecard AG startet Aktienrückkaufprogramm in Höhe von bis zu 200 Mio. EUR
18. Oktober 2019, 16:04
Original-Research: ad pepper media International N.V. (von First Berlin Equity Research GmbH): Hinzufügen
18. Oktober 2019